- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
PlantForm Will Challenge Merck's Dominance for Pembrolizumab
PlantForm will use tobacco plants to develop antibodies for its checkpoint inhibitor pembrolizumab biosimilar.
An Ontario, Canada, biotech company that uses tobacco plants to cultivate antibodies for biosimilar production said it will initiate development of a biosimilar pembrolizumab for the Brazilian market. Pembrolizumab (Keytruda) is a “programmed death” (PD) inhibitor that counteracts tumor cells’ ability to deactivate the immune system response to malignant cells. It is used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
PlantForm uses tobacco plants rather than animal cells to develop antibodies for use in biologics production. Antibody genes are merged with plant bacteria to “infect” the tobacco plants and cause them to produce antibodies, a process that takes about 10 days, according to company information. The company touts this as a way to avoid some of the complexities of standard production techniques that use animals and bioreactors.
PlantForm is partnering with PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz to create the pembrolizumab biosimilar. Merck is expected to lose patent exclusivity protection for Keytruda in the United States, European Union, and Brazil in 2028, allowing a potential entry point for biosimilars. “We want to make a difference in this market by transferring an innovative technology that will bring a low cost biosimilar pembrolizumab to Brazil,” said Germana Regazzi, director of PlantPraxis.
PlantPraxis is a joint venture between PlantForm do, which is a subsidiary of PlantForm, and Axis Biotech Brazil. Bio-Manguinhos is a division of the Brazilian Ministry of Health that furthers the development of technology and production of vaccines, among other activities.
According to PlantPraxis, the pembrolizumab market is expected to reach $25 billion by 2025, making it a potentially lucrative target for biosimilar competitors. PlantPraxis is not alone in cultivating ambitions for participation in this market. NeuClone Pharmaceuticals of Sydney, Australia, announced in September 2020 that it is working to develop biosimilars for pembrolizumab and nivolumab (Opdivo), another PD inhibitor.
PlantForm has other biosimilars in development, including versions of trastuzumab and ranibizumab, which treat forms of cancer and macular degeneration, respectively.
Also of Note
For further reading about the development of PD inhibitor biosimilars, click here.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
